Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
Efficacy of addition of the anti-inflammatory, IV glutathione to standard ketamine IV therapy in major depressive disorder. Psychiatry Research 337 (2024): 115949
We used thematic content analysis to extract information, and presented a narrative review account of the findings
1,2 The first-in-class agent targets the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors, offering a unique metabolic profile that separates it from currently available dual-agonists, such as tirzepatide (Zepbound
Its 2022 disclosure by Coskun and colleagues (Cell Metabolism) marked a deliberate extension of the dual-incretin agonist concept pioneered by tirzepatide, adding glucagon receptor engagement to the pharmacological palette
10.1007/s00125-009-1384-x 60
c) Health Equity Concerns : Access disparities remain significant, with many patients unable to afford these medications out of pocket
